Lesson plan
EGX-A
EGX-A is a serotonin 5-HT 2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a full agonist of the serotonin 5-HT 2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B receptor, is much more potent as a serotonin 5-HT 2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of January 2024, it is in the preclinical research stage of development.
Article summary
EGX-A is a serotonin 5-HT 2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a full agonist of the serotonin 5-HT 2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B receptor, is much more potent as a serotonin 5-HT 2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of January 2024, it is in the preclinical research stage of development.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.